Iloprost

Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research^[1][2][3][4]. In Vitro: Prostacyclin (PGI2) is synthesised in oviductal fluid and enhance the embryo development^[1].
Iloprost is an PGI2 analog, and affects maturation and developmental competence of bovine oocytes^[1].
Iloprost (0.5 μM; 22-24 h) increases blastocyst rates of bovine embryos as well as proportion of expanded blastocysts^[1].
Iloprost (0.5 μM; 22-24 h) assists maturation rates and cumulus cell expansion of bovine oocytes, and increases the mRNA expression of genes related to cumulus expansion^[1].
Iloprost (0.5 μM; 22-24 h) reduces the occurrence of apoptosis in COCs and promotes an anti-apoptotic balance in the transcription of genes involved in apoptosis (BAX and BCL2) ^[1].
In Vivo: Iloprost (0.3 mg/kg/min; via s.c. mini pumps; 33 d) has a significant anti-metastatic activity in a spontaneously metastasizing tumor model in rat^[2].
Iloprost (0.2 mg/kg/d; i.p.; 10 d) attenuates hyperoxia effects and reduces inflammation in the newborn mouse lung, with Cyclooxygenase-2 (COX-2/PTGS2) mediates hyperoxia-induced impairment^[3].
Iloprost (0.2 mg/kg; i.v. or i.p.) exhibits short half-life, and is often administered by means of frequent (every 2-4h) inhalation in treatment^[4].
Comparison of pharmacokinetic parameter in rats and mice^[4]

Animal	Route	Dose (mg/kg)	AUC (ng•h/mL)	F (%)	CL (range) (mL/min/kg)	t1/2λi (min)	t1/2λz (min)
Mice	i.v.	0.2	21.9	100	152	3	15
Rat	i.g.	0.2	2.2	10	/	4	58